Introduction
This supplement deals with a controversial issue: are we ready to accept fluoroquinolones for routine, empirical treatment of respiratory tract infections? When discussing this, one should be aware of the fact that in all countries a majority of antibiotic use is in patients with respiratory tract infections. In adults the commonest reason for antibiotic prescriptions is acute bronchitis, a condition which in the majority of cases is of viral aetiology and which normally should not be treated with antibiotics at all. Today, the only generally accepted indication for fluoroquinolones in patients with respiratory tract infections is acute exacerbation of chronic bronchitis. If other infections are accepted it seems inevitable that the use of fluoroquinolones will increase markedly. In turn, that might lead to increasing problems with resistance.
Issues which should be addressed, and which to a large extent are covered in the articles of this supplement, are the microbiological activity of grepafloxacin against respiratory tract pathogens, its efficacy in lower respiratory tract infections, the possible risk of emergence of resistance and the safety profile. Based on such information, the clinical positioning of grepafloxacin can be discussed.
Antibacterial spectrum
Like older fluoroquinolones, grepafloxacin is highly active against Enterobacteriaceae with MICs normally below 0.1 mg/L. 1, 2 Of respiratory tract pathogens, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae are generally susceptible to grepafloaxacin. [1] [2] [3] [4] Against Streptococcus pneumoniae, Pankuch et al. 5 reported MICs of grepafloxacin ranging between 0.13 and 1 mg/L with an MIC 90 of 0.5 mg/L. These concentrations are well below those reported in plasma and tissues after administration of normal doses. 6, 7 Compared with other fluoroquinolones, the activity of grepafloxacin is similar to that of sparfloxacin and better than those of ciprofloxacin and ofloxacin.
The spectrum of grepafloxacin covers all pathogens likely to cause community-acquired pneumonia. However, its activity against Pseudomonas aeruginosa is about half that of ciprofloxacin, with MICs often above 1 mg/L. 1 Thus, in nosocomial pneumonia, the antibacterial coverage may be incomplete.
Emergence of resistance
Resistance to quinolone antibiotics is chromosomal and has been known to occur stepwise. A consequence of this is that a highly susceptible organism, e.g. an Escherichia coli with an MIC below 0.1 mg/L, will remain sensitive (although with a higher MIC) after one mutation to resistance. Other organisms that are less susceptible, e.g. P. aeruginosa, staphylococci and enterococci, are likely to become resistant after a single mutation.
With grepafloxacin there are no reasons to expect a rapid emergence of resistance in respiratory tract pathogens. A possible exception might be S. pneumoniae. As recently demonstrated by Pan & Fisher, 8 there seem to be two ways in which pneumococci can become resistant to fluoroquinolones. With ciprofloxacin a single mutation in the parC gene coding for topoisomerase IV resulted in a 32-fold increase of the MIC (from 0.25 to 8 mg/L). With sparfloxacin, two mutations were required, one in the parC gene and one in the gyrA gene coding for DNA gyrase. Thus, there should be less risk of emergence of resistance when sparfloxacin is used than when ciprofloxacin is given. For grepafloxacin similar data are not yet available but should offer some indication of the risk of emergence of resistance in pneumococci.
Importantly, there seems to be no cross-resistance to fluoroquinolones in pneumococci resistant to penicillin. 5 Such cross-resistance is very common for co-trimoxazole.
Safety
Quinolones have been related to specific adverse reactions: photoxicity, neurological reactions, e.g. insomnia and dizziness, arthrotoxicity in juvenile animals, 10, 11 Grepafloxacin is metabolized almost entirely in the liver by the cytochrome P450 system; less than 10% of the dose is recovered in the urine. This means that there is a risk of drug-drug interactions. For grepafloxacin such reactions have been seen with theophylline and caffeine. The manufacturer recommends that theophylline doses be reduced by 50% in patients receiving grepafloxacin. Other drugs metabolized by the same cytochrome P450 isoenzyme (CYP IA2) are phenacetin and tamoxifen.
Clinical efficacy
Grepafloxacin has been shown to be as effective as, or more effective than comparator antibiotics in the treatment of acute exacerbations of chronic bronchitis and community-acquired pneumonia. The interesting indication is, of course, community-acquired pneumonia where previous studies of fluoroquinolones have shown lack of efficacy. For example, in a large study in outpatients with symptoms of atypical pneumonia, doxycycline was significantly more effective than fleroxacin. 12 In that study two organisms seemed to problematic for the fluoroquinolone, namely M. pneumoniae and pneumococci.
With grepafloxacin at a dose of 600 mg orally once a day, high cure rates have been reported for patients with infections caused by pneumococci or H. influenzae (Tables  I and II) . In patients with atypical pneumonia, clinical success was reported in 59/60 (98%) of patients with verified M. pneumoniae infections and in 13/14 (93%) of patients with legionella infections (Glaxo-Wellcome, data on file).
Interestingly, in two patients who received low doses of grepafloxacin (200 mg once a day and 400 mg once a day, respectively) emergence of resistance in S. pneumoniae has been seen (Glaxo-Wellcome, data on file). In one strain the MIC increased from 0.008 mg/L pre-therapy to 0.12 mg/L after treatment. The corresponding values for the other strain were <0.002 mg/L and 0.25 mg/L, respectively. Data on the type of resistance in these strains are not available. In patients treated with grepafloxacin 600 mg once a day, no emergence of resistance has been seen in pneumococci.
In patients with acute exacerbations of chronic bronchitis, grepafloxacin at doses of 400 mg or 600 mg once daily was compared with ciprofloxacin 500 mg twice daily. With all treatments, clinical success rates 3-5 days post-treatment were above 80% with no significant differences between the regimens (Glaxo-Wellcome, data on file).
Place of grepafloxacin in therapy
The manufacturer has convincingly documented the efficacy and safety of grepafloxacin in patients with community-acquired pneumonia suitable for oral antibiotic treatment. Based on studies including about 400 patients on grepafloxacin and 200 on ciprofloxacin, it seems likely that these two antibiotics have similar efficacy for the treatment of acute exacerbations of chronic bronchitis.
The new and most interesting issue is whether one should accept the use of a fluoroquinolone as empirical treatment of community-acquired pneumonia. The previous main argument against this has been the poor activity of the older fluoroquinolones against the most important pathogen, S. pneumoniae. With grepafloxacin, it seems clear that this problem has been overcome. Also, grepafloxacin has better activity against M. pneumoniae and C. pneumoniae than most other fluoroquinolones. However, the risk of emergence of resistance in pneumococci cannot yet be assessed and one would like to see more information on mechanisms of resistance, especially 100 whether one or two mutations are required in pneumococci to reach MICs above the concentrations that are achieved in plasma and tissues with normal doses. Like all other antibiotics, grepafloxacin should not be used in acute bronchitis, a condition which in most patients does not require antibiotic treatment. At this stage of development of grepafloxacin, it seems proper to recommend that grepafloxacin can be considered for empirical treatment of community-acquired pneumonia when penicillin-resistant pneumococi represent a major clinical problem and also when there are other reasons, e.g. hypersensitivity, for not using a -lactam antibiotic. Grepafloxacin could also be considered as a possible treatment of atypical pneumonia and of acute exacerbations of chronic bronchitis.
